Biomedical subjects

D R Burt

Publications and source records attributed to D R Burt.

At least 37 records · Page 2Linked to original sources

PubMed1991

GABAA receptor subtypes: from pharmacology to molecular biology.

GABAA receptors are GABA (gamma-aminobutyric acid)-gated chloride channels, which are major mediators of neuronal inhibition in the brain and are modulated by benzodiazepines, barbiturates, alcohol, and other important centrally acting drugs. Although previous pharmacological and biochemical data had suggested a degree of heterogeneity, recent cloning of at least 15 different receptor subunits, thought to be combined in groups of five, indicates that the brain may contain a truly astonishing variety of GABAA receptor subtypes. This review describes the little that is known about these subtypes, emphasizing possible molecular bases of receptor heterogeneity. We also discuss approaches to establishing the subunit composition of subtypes.

Amino Acid Sequence↗

PubMed1991

Generation of two forms of the gamma-aminobutyric acidA receptor gamma 2-subunit in mice by alternative splicing.

gamma-Aminobutyric acidA (GABAA) receptors are multisubunit ligand-gated ion channels which mediate neuronal inhibition by GABA and are composed of at least four subunit types (alpha, beta, gamma, and delta). The gamma 2-subunit appears to be essential for benzodiazepine modulation of GABAA receptor function. In cloning murine gamma 2-subunits, we isolated cDNAs encoding forms of the subunit that differ by the insertion of eight amino acids. LLRMFSFK, in the major intracellular loop between proposed transmembrane domains M3 and M4. The two forms of the gamma 2-subunit are generated by alternative splicing, as demonstrated by cloning and partial sequencing of the corresponding gene. The eight-amino-acid insertion encodes a potential consensus serine phosphorylation site for protein kinase C. These results suggest a novel mechanism for the regulation of the GABAA receptor by protein phosphorylation.

Amino Acid Sequence↗

PubMed1989

Cotransmitters: differential effects of serotonin (5-HT)-depleting drugs on levels of 5-HT and TRH and their receptors in rat brain and spinal cord.

Following codepletion of endogenous serotonin (5-HT, greater than 90%) and thyrotropin-releasing hormone (TRH, 66%) by neonatal treatment with the serotonergic neurotoxin, 5,7-dihydroxytryptamine (DHT), a 33% (n = 12, P less than 0.01) increase in specific TRH receptor binding was observed in adult rat spinal cord (SC) homogenates. A 20-21% increase in TRH receptors was also observed in the medulla/pons (MP) (n = 12, P less than 0.05) and midbrain (MB) (n = 12, P less than 0.02), but no changes were detected in 6 rostral brain regions. The depletion of 5-HT after DHT-treatment was also accompanied by a 34-42% increase in 5-HT1 binding in the SC, MP and MB. Eadie-Hofstee analysis revealed that the changes in TRH receptor levels observed after DHT-lesions were due to an increase in receptor number rather than any significant changes in receptor affinity. Chronic treatment of adult rats with the 5-HT-depleting drugs, p-chlorophenylalanine (PCPA) and reserpine, produced a 90-97% decrease in 5-HT in the SC, MP and MB and elevated 5-HT1 binding above controls in these tissues. However, neither drug treatment caused any significant alterations in the levels of TRH or its receptors in any of these tissues. In conclusion, these results have provided further support for the coexistence of 5-HT and TRH in the MP and SC and revealed possible new areas of such colocalization in the MB. Furthermore, these data have demonstrated that only DHT-treatment, as apposed to PCPA or reserpine, can produce long-lasting codepletion of 5-HT and TRH with simultaneous compensatory up-regulation of their receptor systems in the SC and other caudal tissues.

5,7-Dihydroxytryptamine↗

PubMed1989

Ovariectomy permits progesterone to increase the binding of [3H]spiperone to the anterior pituitary gland in estrogen-primed rats.

The binding of the dopamine (DA) D2 antagonist spiperone to DA receptors in the anterior pituitary gland was evaluated in intact and ovariectomized (OVX) estrogen-primed rats in which circulating levels of progesterone (P) were varied. Nembutal (PB; 35 mg/kg, ip) was administered at 1130 h to intact proestrous animals to prevent the LH-stimulated release of ovarian P. Two hours later some of these intact rats were QVX to remove the endogenous ovarian steroids. Both intact and OVX rats were given exogenous P. All rats were killed on the following morning, and adenohypophysial binding of [3H]spiperone was evaluated at a saturating concentration. The binding in intact PB-blocked rats that received P was only 52% of that in PB-blocked rats that were OVX and received P. The binding of [3H]spiperone in PB-treated rats that were OVX and given P did not differ statistically from that in normal estrous rats. A parallel experiment was conducted on other rats that had been OVX 7 days before the sc implantation (on day 0) of Silastic capsules containing estradiol (E2). Two days later (day 2), some of these rats were injected with Nembutal at 1130 h. Two hours later, the E2 capsules of some rats were removed to simulate ovariectomy; Silastic capsules containing P were implanted into both E2-bearing and non-E2-bearing rats. All rats were killed the following morning (day 3), and the density of adenohypophysial DA receptors was assessed. Binding densities were greatest in rats bearing both E2 and P capsules and in rats from which E2 capsules were removed and replaced with P capsules. We conclude that treatment of OVX rats with the sequential combination of E2 and P increases the density of DA receptors in the anterior pituitary gland. However, in intact rats an additional ovarian product prevents the P-induced increase in the density of adenohypophysial DA receptors.

Animals↗

PubMed1988

Structural and functional basis for GABAA receptor heterogeneity.

When gamma-aminobutyric acid (GABA), the major inhibitory neurotransmitter in vertebrate brain, binds to its receptor it activates a chloride channel. Neurotransmitter action at the GABAA receptor is potentiated by both benzodiazepines and barbiturates which are therapeutically useful drugs (reviewed in ref. 1). There is strong evidence that this receptor is heterogeneous. We have previously isolated complementary DNAs encoding an alpha- and a beta-subunit and shown that both are needed for expression of a functional GABAA receptor. We have now isolated cDNAs encoding two additional GABAA receptor alpha-subunits, confirming the heterogeneous nature of the receptor/chloride channel complex and demonstrating a molecular basis for it. These alpha-subunits are differentially expressed within the CNS and produce, when expressed with the beta-subunit in Xenopus oocytes, receptor subtypes which can be distinguished by their apparent sensitivity to GABA. Highly homologous receptor subtypes which differ functionally seem to be a common feature of brain receptors.

Amino Acid Sequence↗

PubMed1987

Guanine nucleotide regulation of receptor binding of thyrotropin-releasing hormone (TRH) in rat brain regions, retina and pituitary.

Guanine nucleotides inhibited the specific binding of [3H](3-Me-His2)thyrotropin-releasing hormone ([3H]MeTRH) to receptors for TRH in washed homogenates of rat anterior pituitary gland in a dose-related manner. The order of potency (at 100 and 500 microM final) was Gpp(NH)p (a stable analog of GTP) greater than GTP much greater than GDP much greater than cGMP (with the adenine nucleotides being inactive) in the pituitary and various brain regions. Gpp(NH)p at 1 mM caused 17-35% inhibition of [3H]MeTRH binding to different tissues including the pituitary, hypothalamus, retina and nucleus accumbens. A statistically significant nucleotide effect was not observed, however, in the olfactory bulb and medulla/pons membranes. Gpp(NH)p (1 mM) increased the dissociation constants for [3H]MeTRH binding by 1.9- to 2.4-fold in the pituitary, n. accumbens and retinal preparations without altering the apparent binding capacity. These data suggest that TRH receptor binding can be allosterically regulated by guanine nucleotides and provide further evidence for the existence of guanine nucleotide binding protein(s) coupled to the TRH receptor.

Animals↗

PubMed1987

Comparison of the Leicester Micropalliator and the Cardiff Palliator in the relief of postoperative pain.

Two devices for providing patient-controlled, on-demand analgesia were compared for 24 h after abdominal surgery. The Leicester Micropalliator delivered a mandatory background infusion of 1 mg h-1 in addition to on demand bolus doses of morphine 2 mg i.v. while the Cardiff Palliator provided only bolus doses of morphine 2 mg i.v. The Leicester Micropalliator provided analgesia superior or equivalent to that of the Cardiff Palliator in patients who had undergone hysterectomy or cholecystectomy, respectively, and there was no increase in side effects. The total doses of morphine administered over 24 h did not differ significantly between the two devices.

Adult↗

PubMed1986

Experimental spinal cord injury: effects of trauma or ischemia on TRH and muscarinic receptors.

Traumatic spinal cord injury in rats and ischemic spinal cord injury in rabbits were associated with time-dependent, localized decreases in thyrotropin-releasing hormone (TRH) and muscarinic receptor binding. Changes were not evident in the first 24 to 48 hours, consistent with the hypothesis that secondary alterations in spinal cord may occur relatively late after injury. TRH receptor binding, but not muscarinic receptor binding, recovered by 3 weeks following trauma. Since TRH and acetylcholine may serve as excitatory neurotransmitters within the spinal cord, such changes could contribute to the functional neurologic impairment that follows injury.

Animals↗

PubMed1985

Limbic, hypothalamic, cortical and spinal regions are enriched in receptors for thyrotropin-releasing hormone: evidence from [3H]ultrofilm autoradiography and correlation with central effects of the tripeptide in rat brain.

Light microscopic autoradiographic localization of specific recognition sites for thyrotropin-releasing hormone (TRH) was determined on thin sections of rat brain using the potent analogue [3H](3-Me-His2)-TRH ([3H]MeTRH). Microdensitometric analysis of the relative optical densities of TRH receptor labelling revealed the following brain regional enrichment: lateral and cortical amygdaloid nuclei greater than ventral dentate gyrus greater than n. accumbens greater than medial septum greater than piriform cortex greater than paraventricular thalamic and hypothalamic nuclei greater than preoptic area greater than diagonal band of Broca greater than lateral septum greater than I-IV layers of frontoparietal cortex greater than dorsal hippocampus greater than olfactory tubercle greater than caudate putamen; globus pallidus. In the spinal cord the apparent relative enrichment of TRH receptors was: substantia gelatinosa = central canal gray greater than ventral gray greater than dorsal gray (layers III-VII) greater than white matter. This heterogeneous distribution of TRH binding sites correlated well with our previous data obtained from membrane binding studies. Furthermore, the specific anatomical localization of receptors for TRH in many nuclei was consistent with those loci involved in the mediation of many physiological and behavioural actions of the peptide in rodent brain.

Animals↗

PubMed1984

Characterization and autoradiographic localization of TRH receptors in sections of rat brain.

Receptors for thyrotropin-releasing hormone (TRH) in rat brain have been localized autoradiographically by exposing tritium-sensitive film to sections labeled with [3H]3-Me-His2-TRH. Greatest grain density was found over certain nuclei of the amygdala, with considerable density over several other forebrain areas. Properties of TRH receptor binding in frozen sections closely resembled those of receptors in fresh membrane fragments.

Amygdala↗

PubMed1984

TRH receptors in fish.

The brains of goldfish and other teleosts contain high-affinity binding sites for [3H][3-methyl-His2]thyrotropin-releasing hormone [( 3H]MeTRH) which closely resemble TRH receptors in mammalian brain and pituitary gland in apparent dissociation constant (KD = 3-4 nM), in pharmacology for eight TRH analogs, and in exhibiting marked regional differences in the density of binding sites, with highest binding in the cerebrum and lowest in the cerebellum. Fish brain differs from mammalian brain in containing a prominent additional class of much lower affinity [3H]MeTRH binding sites (KD about 15 microM), of unknown nature, which also exhibit regional differences. Fish pituitary glands contain high-affinity [3H]MeTRH binding sites, but insufficient tissue has prevented full characterization. Little or no saturable binding of [3H]MeTRH was detected in several goldfish peripheral tissues.

Animals↗

PubMed1984

Sulfhydryl groups in receptor binding of thyrotropin-releasing hormone to rat amygdala.

Binding of [3H]-[3-Me-His2]thyrotropin-releasing hormone [( 3H]MeTRH) to TRH receptors in rat amygdala was decreased by sulfhydryl reagents in a time-, temperature-, and concentration-dependent manner. A pronounced reduction in receptor density, with little or no change in binding affinity, was apparent following disulfide bond reduction by dithiothreitol (DTT), alkylation of thiol groups by N-ethylmaleimide (NEM), and their oxidation by 5,5'-dithiobis (2-nitrobenzoic acid). Heavy metals (Cd2+, Hg2+), which complex with reactive -SH residues, also potently inhibited binding. The pharmacological specificity of residual [3H]MeTRH binding in chemically modified amygdala membranes was the same as that in control preparations. Sequential exposure to thiol reagents, in the presence or absence of cations, revealed possible additive effects. Pretreatment of membranes with TRH (10(-8) - 10(-6) M), and its continued presence during modification, afforded protection against DTT and NEM. These results indicate the possible importance of thiol groups in the maintenance of TRH receptor conformation.

Amygdala↗

PubMed1984

Modulation of receptors for thyrotropin-releasing hormone by benzodiazepines: brain regional differences.

The benzodiazepines (BZDs) chlordiazepoxide (CDE), diazepam (DZM), and flurazepam (FLM) inhibited receptor binding for thyrotropin-releasing hormone (TRH) with low micromolar potency. In contrast, numerous other categories of drugs were previously shown to be inactive. Scatchard analysis of competition data suggested that the BZDs reduced TRH receptor affinity, consistent with competitive inhibition. Receptors from amygdala, retina, and pituitary appeared more sensitive to inhibition by BZDs than those from hypothalamus, hippocampus, spinal cord, or cerebellum. The latter four regions also gave shallower inhibition curves. CDE revealed an apparently biphasic dissociation of [3-Me-His2]TRH([3H]MeTRH) from amygdala membranes at 4 degrees C, with kinetics similar to those with TRH. These results suggest that TRH receptors in the brain are heterogeneous and that certain BZDs in high therapeutic concentrations may exert central effects through actions at TRH receptors or coupled proteins.

Animals↗

PubMed1984

Ovarian steroids modulate the release of dopamine into hypophysial portal blood and the density of anterior pituitary [3H]spiperone-binding sites in ovariectomized rats.

The concentrations of dopamine (DA) in pituitary stalk plasma and the number of DA D-2 receptor sites in the anterior pituitary gland were evaluated in ovariectomized (OVX) rats treated for 48-78 h with estradiol (E2) or vehicle and for 2-30 h with progesterone (P) or vehicle. Only the combined administration of E2 for 72-78 h and P for 24-30 h altered the release of DA into pituitary stalk blood and the number of dopaminergic binding sites in the anterior pituitary gland. The DA concentrations in pituitary stalk plasma 72 h after initiation of treatment were 1.9 +/- 0.3 (mean +/- SEM), 2.6 +/- 0.2, and 2.4 +/- 0.3 ng/ml in OVX rats treated with vehicle, E2, and P alone, respectively, and were increased significantly to 4.3 +/- 0.4 ng/ml in E2- and P-treated rats. The binding of [3H] spiperone to DA D-2 receptors was measured by a single point assay in homogenates of the individual anterior pituitary glands obtained from the same rats. Anterior pituitary tissue was incubated with 0.4 nM [3H]spiperone in the presence or absence of 10(-6) M (+)butaclamol. Binding was similar in all animals except those treated with E2 and P, in which a significant increase occurred. Three days after initiation of treatment, binding was equivalent to 49.8 +/- 5.8, 51.3 +/- 5.1, and 55.4 +/- 4.9 fmol/mg protein in OVX rats treated with vehicle, E2, and P, respectively. In contrast, a significant increase in binding to 83.7 +/- 4.6 fmol/mg protein was observed in rats given E2 and P. No differences in either parameter were apparent 48 h after starting the steroid/vehicle treatment, nor were there any differences between morning and afternoon values in any single group. Scatchard analyses were made on the binding kinetics of DA receptors in anterior pituitary glands obtained from additional rats, and 1.5- to 2-fold increases in the density of sites were observed in animals that had received both E2 and P, while the apparent affinity of the receptors was unchanged. We conclude that treatment with the combination of E2 and P is required to increase the release of DA into hypophysial portal blood and that it also increases the density of DA receptors within the anterior pituitary gland.

Animals↗

PubMed1983

Micromolar substance P reduces spinal receptor binding for thyrotropin-releasing hormone--possible relevance to neuropeptide coexistence?

Receptors for thyrotropin-releasing hormone (TRH) on membranes of rat spinal cord (SC) were labeled with [3H](3-Me-His2)TRH ([3H]MeTRH) (dissociation constant = 3.6 +/- 0.8 (6) nM). Substance P (SP) caused a concentration-dependent inhibition of TRH receptor binding in the micromolar range (43 +/- 4 (6)% at 50 microM). Scatchard analyses of competition data revealed that 50 microM SP reduced TRH receptor number (40-66%, P less than 0.05) with little or no effect on affinity. SP appeared more potent in reducing [3H]MeTRH binding to ventral cord membranes than those of dorsal or whole SC. A number of SP analogs also reduced TRH receptor binding in a dose-related manner but with different potencies. In contrast, various amino acids and serotonin (250 microM) produced little or no inhibition of [3H]MeTRH binding, and cholecystokinin, Leu- and Met-enkephalins, angiotensin II, LH-RH, bombesin and somatostatin were also markedly less potent than SP. Although it is unclear whether spinal TRH receptors are ever exposed to micromolar concentrations of SP in vivo, the reported colocalization of these neuropeptides in raphe efferents to the SC suggests that our findings may be of physiological relevance.

Animals↗

PubMed1983

Codepletion of serotonin and TRH induces apparent supersensitivity of spinal TRH receptors.

Thyrotropin-releasing hormone (TRH), substance P (SP) and serotonin (5-HT) coexist in raphe efferents to the spinal cord. Lesions of these serotonergic projections by intracisternal injection of 5,7-dihydroxytryptamine (50 micrograms) in rat pups resulted in 93% and 65% decreases in 5-HT and TRH content of adult rat spinal cords, respectively. This codepletion induced a 30-40% increase in binding of [3H][3-Me-His2]TRH [( 3H]MeTRH) to TRH receptors. The affinity and pharmacological specificity of [3H]MeTRH binding to control and DHT-lesioned cords appeared closely similar.

5,7-Dihydroxytryptamine↗

PubMed1983

Benzodiazepines compete for thyrotropin-releasing hormone receptor binding: micromolar potency in rat pituitary, retina and amygdala.

In screening neuroactive compounds for their possible interaction with rat thyrotropin-releasing hormone (TRH) receptors, some benzodiazepines were found to compete relatively potently for specific [3H](3-Me-His2)TRH [( 3H]MeTRH) binding. The profile of activity (chlordiazepoxide greater than diazepam greater than flurazepam greater than lurazepam greater than flunitrazepam) was almost identical for washed pituitary, retina and amygdala preparations. Corresponding Ki values for the latter region were (microM): 0.33, 3.24, 17.4 for the 3 most active inhibitors. Other (47) neuroactive substances exhibited little activity on [3H]MeTRH binding. All benzodiazepines tested were competitive inhibitors in the three tissues. These data support previous evidence for a close similarity of TRH receptors in the pituitary gland and central nervous system, and invoke the possibility of TRH receptor-mediated effects for some benzodiazepines.

Amygdala↗

PubMed1983

Biochemical and autoradiographic studies of TRH receptors in sections of rabbit spinal cord.

Receptors for thyrotropin-releasing hormone (pGlu-His-Pro-NH2, TRH) on thaw-mounted sections of rabbit spinal cord have been identified biochemically and visualized by light microscopic autoradiography. Binding of [3H] [3-Me-His2]TRH to 20 microns sections exhibited high apparent affinity and a pharmacological specificity almost identical to that previously demonstrated for spinal TRH receptors in membranes. In autoradiograms, the highest density of TRH receptors appeared in the substantia gelatinosa of the dorsal gray and around the central canal, with intermediate levels in the ventral gray.

Animals↗